Targeting β-cell mass in type 2 diabetes:: Promise and limitations of new drugs based on incretins

被引：89

作者：

Salehi, Marzieh ^{[1
]}

Aulinger, Benedikt A. ^{[1
]}

D'Alessio, David A. ^{[1
]}

机构：

[1] Univ Cincinnati, Dept Med, Div Endocrinol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA

来源：

ENDOCRINE REVIEWS | 2008年 / 29卷 / 03期

关键词：

D O I：

10.1210/er.2007-0031

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic beta-cells or a reduction in beta-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on beta-cell physiology as well as by expanding or at least maintaining beta-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

引用

页码：367 / 379

页数：13

共 163 条

[51] β-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes:: A new analysis [J].

Ferrannini, E ;

Gastaldelli, A ;

Miyazaki, Y ;

Matsuda, M ;

Mari, A ;

DeFronzo, RA .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (01) :493-500

[52] DYNAMICS OF BETA-CELL MASS IN THE GROWING RAT PANCREAS - ESTIMATION WITH A SIMPLE MATHEMATICAL-MODEL [J].

FINEGOOD, DT ;

SCAGLIA, L ;

BONNERWEIR, S .

DIABETES, 1995, 44 (03) :249-256

[53] Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans [J].

Flint, A ;

Raben, A ;

Astrup, A ;

Holst, JJ .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (03) :515-520

[54] RESPONSE OF TRUNCATED GLUCAGON-LIKE PEPTIDE-1 AND GASTRIC-INHIBITORY POLYPEPTIDE TO GLUCOSE-INGESTION IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS - EFFECT OF SULFONYLUREA THERAPY [J].

FUKASE, N ;

MANAKA, H ;

SUGIYAMA, K ;

TAKAHASHI, H ;

IGARASHI, M ;

DAIMON, M ;

YAMATANI, K ;

TOMINAGA, M ;

SASAKI, H .

ACTA DIABETOLOGICA, 1995, 32 (03) :165-169

[55] Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes [J].

Gault, VA ;

Irwin, N ;

Green, BD ;

McCluskey, JT ;

Greer, B ;

Bailey, CJ ;

Harriott, P ;

O'Harte, FPM ;

Flatt, PR .

DIABETES, 2005, 54 (08) :2436-2446

[56] Exenatide (Exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight [J].

Gedulin, BR ;

Nikoulina, SE ;

Smith, PA ;

Gedulin, G ;

Nielsen, LL ;

Baron, AD ;

Parkes, DG ;

Young, AA .

ENDOCRINOLOGY, 2005, 146 (04) :2069-2076

[57]

GHOFAILI KA, 2001, TRANSPLANTATION, V83, P24

[58] cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic β-cells [J].

Gomez, E ;

Pritchard, C ;

Herbert, TP .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (50) :48146-48151

[59] Glucagon-like peptide 1(7-36) amide stimulates exocytosis in human pancreatic β-cells by both proximal and distal regulatory steps in stimulus-secretion coupling [J].

Gromada, J ;

Bokvist, K ;

Ding, WG ;

Holst, JJ ;

Nielsen, JH ;

Rorsman, P .

DIABETES, 1998, 47 (01) :57-65

[60] Neural regulation of glucagon-like peptide-1 secretion in pigs [J].

Hansen, L ;

Lampert, S ;

Mineo, H ;

Holst, JJ .

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2004, 287 (05) :E939-E947

← 1 2 3 4 5 6 7 8 9 10 →